Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs)

Area of Science:

• Medicinal Chemistry
• Genetics
• Pharmacology

Background:

• Nonsense mutations lead to premature termination codons (PTCs), resulting in truncated, non-functional proteins and causing mendelian genetic diseases.
• Translational readthrough-inducing drugs (TRIDs) offer a therapeutic strategy to overcome PTCs and restore full-length protein expression.

Purpose of the Study:

• To review oxadiazoles as TRIDs for treating genetic disorders caused by nonsense mutations.
• To compare the mechanisms of action of different TRID classes, including novel oxadiazole derivatives and aminoglycosides.
• To present recent findings on TRIDs for restoring cystic fibrosis transmembrane regulator (CFTR) protein production.

Main Methods:

• Review of existing literature on TRIDs and oxadiazole derivatives.
• Analysis of TRID mechanisms, focusing on PTCs and protein expression.
• Evaluation of candidate TRIDs, including oxadiazole-based compounds, for CFTR protein restoration.

Main Results:

• Oxadiazoles represent a promising class of TRIDs with potential therapeutic applications.
• Novel oxadiazole derivatives demonstrate efficiency in restoring functional protein expression, exemplified by CFTR.
• Comparison with aminoglycosides highlights distinct mechanisms and potential advantages of oxadiazoles.

Conclusions:

• Oxadiazoles are effective TRIDs for genetic diseases stemming from nonsense mutations.
• Further development of oxadiazole-based TRIDs, alongside complementary strategies, holds significant therapeutic potential.
• Careful consideration of development opportunities and challenges is crucial for advancing small molecules as TRIDs.